FGF19 and metabolic dysfunction-associated steatotic liver disease: Conversely, hepatic KLB and FGFR4 expression are increased in patients with MASLD/MASH, suggesting potential disruption in the FGF19/KLB/FGFR4 signaling pathway (DePaoli et al., 2019).